Anti-TSLP treatment may extend care to a broad range of severe asthma patients
17 Jul 2024
byDr. Hassan Burhan, Royal Liverpool University Hospital, Liverpool, UK
Inhibition of thymic stromal lymphopoietin (TSLP), a crucial epithelial cytokine with broad effects on airway inflammation, has emerged as a potential therapeutic approach for severe asthma. At an industry-sponsored symposium during Autumn Respiratory Seminar (ARS) 2023 jointly organized by the Hong Kong Thoracic Society and the CHEST Delegation Hong Kong and Macau, Dr Hassan Burhan of the Royal Liverpool University Hospital, Liverpool, UK, discussed the role of epithelial cytokines in inflammation and airway hyperresponsiveness (AHR), and reviewed the clinical evidence supporting the use of tezepelumab, an anti-TSLP monoclonal antibody (mAb), among patients with severe asthma of diverse phenotypes. He also shared a case illustrating tezepelumab use in severe uncontrolled asthma (SUA).
